The deal formalizes a division of labor where Innovent leverages its expansive oncology sales infrastructure to drive adoption of Verzenios, a therapy already integrated into China’s National Reimbursement Drug List. Since its inclusion in 2021 and subsequent 2025 renewal, the drug has gained significant traction for treating both early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer.
In section Releases
Innovent and Eli Lilly Expand Partnership for Breast Cancer Drug in China
Innovent Biologics has secured the exclusive commercialization rights for Eli Lilly’s CDK4 & 6 inhibitor Verzenios in mainland China, marking the eighth collaboration between the two pharmaceutical firms. Under the new agreement, Innovent will manage all local marketing and distribution while Lilly retains manufacturing and development responsibilities.
Dr. Michael Yu, CEO of Innovent, noted that this partnership brings the company's portfolio of on-market products to 19. For Lilly, the arrangement aligns with a broader strategy to accelerate the delivery of its oncology pipeline in China, following recent regulatory approvals for other precision therapies. The collaboration aims to capitalize on existing reimbursement coverage to broaden patient access to the drug across the country.
Comments (0)
No comments yet. Be the first!